Skip to content

A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study

A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study - MONOTREAT

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01747655
Acronym
MONOTREAT
Enrollment
64
Registered
2012-12-12
Start date
2013-02-28
Completion date
2015-07-31
Last updated
2016-10-13

For informational purposes only โ€” not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Early Observational Advanced, Parkinson's Disease

Brief summary

Patients with advanced Parkinson's Disease experience a range in the severity of their motor fluctuations. The rationale for this Post Marketing Observational Study is to demonstrate the benefits of Duodopa treatment on Parkinson's Disease patients entering the advanced stage of the disease whose motor fluctuations have become troublesome and complicate management with oral therapy. The aim of this post-marketing observational study is to assess the effect of Duodopa treatment on activities of daily living in advanced Parkinson's Disease participants characterised by either 2-4 hours of off time or 2 hours of non-troublesome or troublesome dyskinesia daily, supported by a Unified Parkinson's Disease Rating Scale Total Score in the best on state of at least 40 points at baseline.

Detailed description

Data are recorded from visits most closely aligned with the planned periods of Visit 0 (V0): Baseline (After decision to use the temporary naso-duodenal tube (approximately 2-14 days) and after signature of the Patient Authorization/Informed Consent Form); Visit 1 (V1): At discharge from hospital; Visit 2 (V2): 3 months after discharge; Visit 3 (V3): 6 months after discharge; Visit 4 (V4): 12 months after discharge. All participants have a temporary naso-duodenal tube used initially with the infusion pump to determine if the participant responds favorably to this method of treatment and to optimize the dose of Duodopa before permanent treatment is started. Participants who choose a treatment other than Duodopa after the temporary naso-duodenal test phase are considered for the Standard of Care group. Participants who go on to select Apomorphine pump or Deep Brain Stimulation at any stage are not eligible to continue in this group or to continue in the observational period of study. Participants who continue to with Duodopa treatment after the the temporary naso-duodenal test phase are the Duodopa group.

Interventions

None listed

Sponsors

AbbVie (prior sponsor, Abbott)
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Has advanced levodopa-responsive Parkinson's disease * The decision to treat with Duodopa is made by the physician in accordance with the local label (Summary of Product Characteristics; product label) prior to any decision to approach the patient to participate in this study * Parkinson's Disease (PD) medicinal treatment is unchanged for at least four weeks prior to baseline * Takes oral medication four or more times daily * Either has 2-4 hours of off time or 2 hours of non-troublesome or troublesome dyskinesia daily supported by a Unified Parkinson's Disease Rating Scale (UPDRS) Total Score in the best on state of at least 40 points at baseline; based on documented medical history

Exclusion criteria

* Use of Deep Brain Stimulation (DBS), Apomorphine pump or Duodopa treatment prior to baseline visit * Severe dementia based on a Mini-Mental State Examination (MMSE) of \< 24

Design outcomes

Primary

MeasureTime frameDescription
Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital DischargeBaseline (Week 0) and 12 months after hospital dischargeThe UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to 13 questions, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. UPDRS scores during On time (when PD symptoms are well controlled by the drug) are presented. Last observation carried forward (LOCF) was used for missing data.

Secondary

MeasureTime frameDescription
Percentage of Participants Who Continued With Jejunal Extension Tube of the Percutaneous Endoscopic Gastrostomy (PEG-J) Treatment14 daysThe percentage of participants who continued with PEG-J treatment after treatment via temporary naso-jejunal tube.
Primary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the Study12 monthsThe primary reasons for stopping treatment with Duodopa or for discontinuing the study.
Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeThe UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of off times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.
Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeThe UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of off times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.
Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeThe UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of off times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.
Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeThe UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of off times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.
Unified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeThe UPDRS III questionnaire consists of 14 questions on motor examinations rated from 0 (absent/normal) to 4 (extreme impairment). Questions 20-26 are multi-part questions in that they are evaluated separately for multiple body parts (for example, for the left and right hand). Counting each of these assessments leads to a total of 27 answers. The UPDRS III score ranges from 0 to 108 with higher values indicating greater impairment and was calculated as the sum of the 27 answers provided to the 14 questions. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.
Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeThe UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to 13 questions, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. UPDRS scores during On time (when PD symptoms are well controlled by the drug) are presented. n=the number of participants with data at baseline and given time point.
Parkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0), at discharge from hospital, and 3, 6, and 12 months after hospital dischargeParticipants were asked to state how often they had encountered certain problems over the past four weeks using the following rating scale: Never (0), occasionally (1), sometimes (2), often (3), always or cannot do at all (4). The PDQ-8 summary index was derived as the sum of the single items divided by 32. Scores range from 0 to 100. A higher summary index score indicates a higher impairment of quality of life. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.
Healthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeParticipants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.
Healthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeParticipants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.
Healthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeParticipants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at given time point.
Healthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeParticipants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at given time point.
Healthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeParticipants were asked about their utilization of healthcare resources within the previous 3 months , including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.
Non-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (Week 0) and 3, 6, and 12 months after hospital dischargeNon-motor symptoms assessed over the previous month were scored with respect to severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) and with respect to frequency (1 = rarely, 2 = often, 3 = frequent, 4 = very frequent). The total NMSS score ranges from 0 to 360 with higher values indicating greater impairment and was calculated as the sum of all individual score values. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.

Participant flow

Participants by arm

ArmCount
Duodopa
Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)
64
Total64

Withdrawals & dropouts

PeriodReasonFG000FG001
PEG-J Period (Duodopa Treatment)Investigator Decision (Medical Event)50
PEG-J Period (Duodopa Treatment)Lost to Follow-up10
PEG-J Period (Duodopa Treatment)Patient Decision80

Baseline characteristics

CharacteristicDuodopa
Age, Continuous70.4 years
STANDARD_DEVIATION 7.8
Sex: Female, Male
Female
25 Participants
Sex: Female, Male
Male
39 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
โ€” / โ€”
other
Total, other adverse events
10 / 64
serious
Total, serious adverse events
14 / 64

Outcome results

Primary

Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to 13 questions, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. UPDRS scores during On time (when PD symptoms are well controlled by the drug) are presented. Last observation carried forward (LOCF) was used for missing data.

Time frame: Baseline (Week 0) and 12 months after hospital discharge

Population: MAS population

ArmMeasureValue (MEAN)Dispersion
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge-2.1 units on a scaleStandard Deviation 6.9
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge1.4 units on a scaleStandard Deviation 5.1
Secondary

Healthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital Discharge

Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (NUMBER)
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeOvernight hospital stay at Baseline (n=64)14.1 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeOvernight hospital stay at 3 months (n=53)9.4 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeOvernight hospital stay at 6 months (n=49)10.2 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeOvernight hospital stay at 12 months (n=47)6.4 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeVisit at emergency room at Baseline (n=64)10.9 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeVisit at emergency room at 3 months (n=53)3.8 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeVisit at emergency room at 6 months (n=49)14.3 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeVisit at emergency room at 12 months (n=47)8.5 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeCalls for immediate assistance at Baseline (n=64)25.0 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeCalls for immediate assistance at 3 months (n=53)26.4 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeCalls for immediate assistance at 6 months (n=49)6.1 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital DischargeCalls for immediate assistance at 12 months (n=46)4.3 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital Discharge911/Emergency at Baseline (n=64)4.7 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital Discharge911/Emergency at 3 months (n=53)1.9 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital Discharge911/Emergency at 6 months (n=49)4.1 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital Discharge911/Emergency at 12 months (n=46)4.3 percentage of participants
Secondary

Healthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital Discharge

Participants were asked about their utilization of healthcare resources within the previous 3 months , including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (NUMBER)
DuodopaHealthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital DischargeBaseline (n=64)35.9 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital Discharge3 months (n=53)17.0 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital Discharge6 months (n=49)24.5 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital Discharge12 months (n=47)14.9 percentage of participants
Secondary

Healthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaHealthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (n=64)8.7 office visitsStandard Deviation 9.8
DuodopaHealthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=53)-3.0 office visitsStandard Deviation 8
DuodopaHealthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=49)-2.7 office visitsStandard Deviation 9.8
DuodopaHealthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=47)-2.1 office visitsStandard Deviation 18.5
Secondary

Healthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaHealthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeBaseline (n=64)11.2 visits at homeStandard Deviation 31.4
DuodopaHealthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=53)0.8 visits at homeStandard Deviation 25.8
DuodopaHealthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=49)-1.0 visits at homeStandard Deviation 21.5
DuodopaHealthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=47)4.0 visits at homeStandard Deviation 31.5
Secondary

Healthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital Discharge

Participants were asked about their utilization of healthcare resources within the previous 3 months, including total number of office visits, total number of visits at home for Parkinson's disease, total number of emergency situations (overnight hospital stay, visit at emergency room, calls for immediate assistance \[family/friend)\], and calls to 911/emergency), received assistance at home (family/friend or paid caregiver), and falls. n=the number of participants with data at given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (NUMBER)
DuodopaHealthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargeFamily/friend at Baseline (n=64)59.4 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargeFamily/friend at 3 months (n=53)49.1 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargeFamily/friend at 6 months (n=49)44.9 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargeFamily/friend at 12 months (n=47)46.8 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargePaid caregiver at Baseline (n=64)10.9 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargePaid caregiver at 3 months (n=53)24.5 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargePaid caregiver at 6 months (n=49)24.5 percentage of participants
DuodopaHealthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital DischargePaid caregiver at 12 months (n=47)25.5 percentage of participants
Secondary

Non-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

Non-motor symptoms assessed over the previous month were scored with respect to severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) and with respect to frequency (1 = rarely, 2 = often, 3 = frequent, 4 = very frequent). The total NMSS score ranges from 0 to 360 with higher values indicating greater impairment and was calculated as the sum of all individual score values. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaNon-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=44,5)-39.5 units on a scaleStandard Deviation 38
DuodopaNon-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=40,5)-33.7 units on a scaleStandard Deviation 33.1
DuodopaNon-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=38,6)-33.9 units on a scaleStandard Deviation 40.6
DuodopaNon-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=40,10)-32.5 units on a scaleStandard Deviation 40.1
Standard of CareNon-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=40,10)-32.7 units on a scaleStandard Deviation 45.9
Standard of CareNon-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=44,5)-8.0 units on a scaleStandard Deviation 14.6
Standard of CareNon-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=38,6)-10.3 units on a scaleStandard Deviation 15.2
Standard of CareNon-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=40,5)-45.0 units on a scaleStandard Deviation 64.5
Secondary

Parkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

Participants were asked to state how often they had encountered certain problems over the past four weeks using the following rating scale: Never (0), occasionally (1), sometimes (2), often (3), always or cannot do at all (4). The PDQ-8 summary index was derived as the sum of the single items divided by 32. Scores range from 0 to 100. A higher summary index score indicates a higher impairment of quality of life. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0), at discharge from hospital, and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaParkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge3 months after discharge (n=46,6)-15.7 units on a scaleStandard Deviation 17.8
DuodopaParkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge6 months after discharge (n=43,6)-15.4 units on a scaleStandard Deviation 17.2
DuodopaParkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge12 months after discharge (n=41,6)-12.3 units on a scaleStandard Deviation 20.6
DuodopaParkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge12 months after discharge LOCF (n=42,10)-12.1 units on a scaleStandard Deviation 20.4
Standard of CareParkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge12 months after discharge LOCF (n=42,10)-8.1 units on a scaleStandard Deviation 16.2
Standard of CareParkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge3 months after discharge (n=46,6)-2.6 units on a scaleStandard Deviation 6.4
Standard of CareParkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge12 months after discharge (n=41,6)-3.6 units on a scaleStandard Deviation 7.5
Standard of CareParkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge6 months after discharge (n=43,6)-10.9 units on a scaleStandard Deviation 20.3
Secondary

Percentage of Participants Who Continued With Jejunal Extension Tube of the Percutaneous Endoscopic Gastrostomy (PEG-J) Treatment

The percentage of participants who continued with PEG-J treatment after treatment via temporary naso-jejunal tube.

Time frame: 14 days

Population: MAS population

ArmMeasureValue (NUMBER)
DuodopaPercentage of Participants Who Continued With Jejunal Extension Tube of the Percutaneous Endoscopic Gastrostomy (PEG-J) Treatment90.6 percentage of participants
Secondary

Primary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the Study

The primary reasons for stopping treatment with Duodopa or for discontinuing the study.

Time frame: 12 months

Population: Participants in the MAS who stopped treatment with Duodopa or discontinued from study.

ArmMeasureGroupValue (NUMBER)
DuodopaPrimary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the StudyPatient decision9 participants
DuodopaPrimary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the StudyInvestigator decision (due to medical event)8 participants
DuodopaPrimary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the StudyInvestigator decision (other than medical event)2 participants
DuodopaPrimary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the StudyDoes not feel has adequate support after discharge1 participants
DuodopaPrimary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the StudyDoes not wish to carry the pump / device system1 participants
DuodopaPrimary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the StudyDoes not wish to undergo the PEG-J procedure1 participants
DuodopaPrimary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the StudyLost to follow-up1 participants
Secondary

Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to 13 questions, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. UPDRS scores during On time (when PD symptoms are well controlled by the drug) are presented. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,7)-4.4 units on a scaleStandard Deviation 5.6
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=44,6)-3.4 units on a scaleStandard Deviation 4.9
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)-1.8 units on a scaleStandard Deviation 7.1
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,7)0.9 units on a scaleStandard Deviation 6
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=44,6)-1.5 units on a scaleStandard Deviation 2.3
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)0.5 units on a scaleStandard Deviation 5.3
Secondary

Unified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

The UPDRS III questionnaire consists of 14 questions on motor examinations rated from 0 (absent/normal) to 4 (extreme impairment). Questions 20-26 are multi-part questions in that they are evaluated separately for multiple body parts (for example, for the left and right hand). Counting each of these assessments leads to a total of 27 answers. The UPDRS III score ranges from 0 to 108 with higher values indicating greater impairment and was calculated as the sum of the 27 answers provided to the 14 questions. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=51)-12.9 units on a scaleStandard Deviation 16.2
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=49)-8.9 units on a scaleStandard Deviation 12.3
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=46)-8.7 units on a scaleStandard Deviation 12.6
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=61)-8.9 units on a scaleStandard Deviation 12.6
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=61)-8.7 units on a scaleStandard Deviation 21.2
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=51)-6.3 units on a scaleStandard Deviation 11.9
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=46)0.3 units on a scaleStandard Deviation 16.5
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=49)-17.0 units on a scaleStandard Deviation 22.6
Secondary

Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of off times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,6)-0.5 units on a scaleStandard Deviation 1.1
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months after (n=44,6)-0.6 units on a scaleStandard Deviation 1
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)-0.4 units on a scaleStandard Deviation 1.2
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=47,14)-0.5 units on a scaleStandard Deviation 1.2
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=47,14)-0.4 units on a scaleStandard Deviation 0.9
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,6)-0.5 units on a scaleStandard Deviation 0.8
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)-0.2 units on a scaleStandard Deviation 1.2
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months after (n=44,6)-0.5 units on a scaleStandard Deviation 1
Secondary

Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of off times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,6)-0.9 units on a scaleStandard Deviation 0.9
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=44,6)-0.9 units on a scaleStandard Deviation 1
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)-0.5 units on a scaleStandard Deviation 1.1
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=47,14)-0.9 units on a scaleStandard Deviation 1.1
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=47,14)-0.6 units on a scaleStandard Deviation 1.1
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,6)-0.3 units on a scaleStandard Deviation 0.5
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)-0.5 units on a scaleStandard Deviation 1.4
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=44,6)-0.3 units on a scaleStandard Deviation 0.5
Secondary

Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of off times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,6)-0.3 units on a scaleStandard Deviation 0.8
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=43,6)-0.3 units on a scaleStandard Deviation 0.8
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)-0.3 units on a scaleStandard Deviation 0.7
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=47,14)-0.3 units on a scaleStandard Deviation 0.8
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=47,14)0.0 units on a scaleStandard Deviation 0.9
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,6)0.2 units on a scaleStandard Deviation 0.4
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)0.3 units on a scaleStandard Deviation 0.8
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=43,6)-0.3 units on a scaleStandard Deviation 0.8
Secondary

Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge

The UPDRS IV questionnaire consists of 4 individual items that assess the degree of dyskinesias (Item 32: duration; Item 33: disability; and Item 34: pain) and clinical fluctuations (Item 39: percentage of off times of the waking day). Individual UPDRS IV item scores range from 0 to 4. Higher scores indicate a higher complication of therapy. Observed values are presented for each visit as well as LOCF at 12 months after discharge. n=the number of participants with data at baseline and given time point.

Time frame: Baseline (Week 0) and 3, 6, and 12 months after hospital discharge

Population: MAS population

ArmMeasureGroupValue (MEAN)Dispersion
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,6)-0.9 units on a scaleStandard Deviation 1
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=44,6-0.9 units on a scaleStandard Deviation 0.9
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)-0.8 units on a scaleStandard Deviation 0.8
DuodopaUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=47,14)-0.8 units on a scaleStandard Deviation 0.9
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months LOCF (n=47,14)-0.4 units on a scaleStandard Deviation 1.1
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 3 months (n=47,6)-0.5 units on a scaleStandard Deviation 1.5
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 12 months (n=41,6)-0.3 units on a scaleStandard Deviation 1
Standard of CareUnified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital DischargeChange from baseline to 6 months (n=44,6-0.7 units on a scaleStandard Deviation 0.5

Source: ClinicalTrials.gov ยท Data processed: Feb 4, 2026